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Development and evaluation of albendazole microcapsule for colonic drug delivery system 
 
ABSTRACT 
 
At present scenario colon specific drug delivery has gainedincreased importance. Colon drug 
delivery system not only used for the treatment of local diseases, associated with the colon but 
also it is a potential site for systemic delivery of therapeutic drug. 
Albendazole is a benzimidazole carbamate broad spectrum oral anthelmetic drug. It is poorly 
water soluble and it undergoes extensive metabolism in the intestine and liver.  
Different batches of Albendazole microcapsules were preparedusing different concentration of 
polymers like Eudragit RS-100, chitosan, HPMC. The microcapsules were then evaluated for 
micromeritic properties, percentage yield, incorporation efficiency, drug content. In vitro 
dissolution profile of each formulation was determined by employing USP XXIII rotating basket 
method. 
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INTRODUCTION 
Colon targeted drug delivery isused to deliver the drugs that are degraded by the digestive 
enzymes in the stomach such as proteins and peptides. The colon is attracting interest as a site 
where poorly absorbed drug molecule may have an improved bioavailability
1
. Colon is 
recognized as having a somewhat less hostile environment with less diversity and intensity of 
activity as compared to stomach and small intestine
2
. Furthermore, the colon has a long retention 
time and appears highly responsive to agents that enhance the absorption of poorly absorbed 
drugs.  Colon is also found to be a promising site when delay in absorption is desirable from 
therapeutic point of view for the treatment of disease that have peak symptoms in early morning 
and that exhibit circadian rhythm, such as rheumatoid arthritis, nocturnal asthma and angina 
pectoris. Colon targeted drug delivery of drugs reduces the systemic side effects
3
. 
Microencapsulation is a process in which tiny particles or a coating to give small capsules with 
many useful properties surrounds droplets. Furthermore the administered dose of a drug is 
subdivided into small units that are spread over a large area of the gastrointestinal tract, which 
may enhance absorption by diminishing localizeddrug concentration
4
. 
Albendazole is a benzimidazole carbamate broad spectrum oral anthelmetic used to treat a 
variety of worm infections caused by nematodes and cestodes
5
. It falls into the BCS class II 
category as has high permeability and low solubility
6
. It is poorly soluble having aqueous 
solubility to be 0.2 mg mL
–1
 at 25 °C. Because of its low aqueous solubility, it is poorly and 
erratically absorbed following oral administration
7,8,9
.  
In present study microcapsules of Albendazole were  formulated for colonic drug delivery  to 
avoid side effects associated with albendazole therapy and to improve pharmacological effect as  
most of the worms reside in large intestinal part and. 
MATERIALS AND METHODS 
Albendazole was obtained from Emzor Pharmaceutical Industries Limited, Lagos Eudragit RS-
100 was obtained from Evans Medical PLC, Lagos, Nigeria, HPMC and chitosan were obtained 
from Revive Technologies, lagos. All other chemicals and reagent used in this study were of 
analytical grade. 
 METHOD OF PREPARATION 
Albendazole microcapsules formulations wereprepared by solvent evaporation method
10
. 
Accurately weighted Eudragit RS‐100, chitosan and HPMC were taken in different ratios as 
shown in table 1. All polymers were dissolved in 30ml of acetone to form a homogenous 
polymers solution. Core material, i.e. Albendazole was dispersed in it and mixed thoroughly.  
This organic phase was slowly poured at 15°C in to liquid paraffin (100 ml) containing 1% 
(w/w) of Span‐80 with stirring at 1000 rpm to form a uniform emulsion. Thereafter, it was 
allowed to attain room temperature and stirring was continued until residual acetone evaporated 
and smooth‐walled, rigid and discrete microcapsules were formed. The microcapsules were 
collected by decantation and the product was washed with petroleum ether (40– 60°C), four 
times and dried at room temperature for 3 hrs. Themicrocapsules were then stored in a 
desiccators over fused calcium chloride. 
EVALUATION OF ALBENDAZOLE MICROCAPSULES 
Micromeritic properties 
The microcapsules are characterized by their micromeritic properties such as bulk density, true 
density, porosity, Hausner’s ratio11. 
Particle size: Determination of average particle size of the Albendazole microcapsules was 
carried out by the optical microscopy method. A minute quantity ofmicrocapsules was spread on 
clean glass slide and average sizes of 100 microcapsules were determined in each batch
12
. 
Percentage yield  
The measured weight was divided by total amount of all non‐volatile components which were 
used for the preparation of microcapsule
13
. 
% yield =(Actual weight of product)/(Total weight of excipient and drug) X 100 
 
Incorporation efficiency: 
In 100 ml volumetric flask 25mg of crushed microcapsuleswere taken and dissolved with small 
quantity of ethanol of the volume is made up to mark with pH 6.8 and stirred for 12 hours. After 
stirring the solution was filtered through Whatman filter paper and from the filtrate appropriate 
dilutions were made and absorbance was measured at 261 nm by using UV‐spectrophotometer14. 
Drug content  
In a 100 ml volumetric flask, 25 mg of crushed microcapsules were taken, and volume was made 
up to mark with pH 7.4. The flask was shaken for 12 hours using an orbital shaker incubator. 
Then the solution was filtered and from the filtrateappropriate dilutions were made and 
absorbance was measured at 261 nm
15
. 
In vitro release studies:  
In vitro dissolution profile of each formulation was determined by employing USP XXIII 
rotating basket method (900 ml of pH 6.8‐phosphate buffer, 100 rpm, 37±0.5 0C). Microcapsules 
equivalent to 150 mg of Albendazole was loaded into the basket of the dissolution apparatus. 
Five milliliters of the sample was withdrawn from the dissolution media at suitable time intervals 
and the same amount was replaced with freshbuffer. The absorbance of the filtrate was 
determined at wavelength of 261 nm by using UV spectrophotometer, against pH 6.8 as blank
16
. 
 
 
 
 
 
 Table 1: Composition of Albendazole microcapsules 
 
Table 2: Characterizationof Albendazole microcapsules 
Batc
h 
Code 
% 
Yield 
 
%Incorporatio
n efficiency (%) 
Mean 
particl
e size 
(µm)  
% 
Drug 
conten
t 
 
Angle 
of 
repos
e 
Bulk 
densit
y 
Tappe
d 
density 
Hausner
s Ratio 
MC1 90±0.0
8 
88.58±0.21 180±2.
5 
96 18.1 0.60 0.62 1.031 
MC2 96±0.1
2 
90.72±0.45 210±3.
2 
90 22.5 0.61 0.63 1.030 
MC3 94±0.3
2 
88.46±0.42 195±1.
5 
93 20.4 0.62 0.64 1.024 
MC4 90±0.4
1 
93.57±0.08 230±3.
6 
94 19.3 0.59 0.61 1.046 
MC5 93±0.3
7 
90.24±0.11 240±1.
8 
95 21.5 0.57 0.59 1.040 
MC6 97±0.4
6 
96.48±0.38 245±3.
5 
98 20.6 0.64 0.66 1.029 
 (Mean± S.D., n=4)   
 
Figure 1: % Incorporation efficiency of Albendazole microcapsules 
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Formulations 
MC1 
MC2 
MC3 
MC4 
MC5 
MC6 
Code Drug (mg) Eudragit 
RS-100 
(mg) 
Chitosan 
(mg) 
HPMC 
(mg) 
Liquid 
paraffin    
(ml) 
Span 80 
(ml) 
Acetone 
(ml) 
MC1 400 300 - - 50 1 30 
MC2 400 - 300 - 50 1 30 
MC3 400 - - 300 50 1 30 
MC4 400 200 100 - 50 1 30 
MC5 400 - 200 100 50 1 30 
MC6 400 200 100 200 50 1 30 
  
 
Figure 2: Comparative in-vitro releasestudy of Albendazole microcapsules 
RESULTS AND DISCUSSION 
Six different microcapsules formulations were prepared by solvent evaporation using different 
polymers ratio. Pure acetone did not dissolve Eudragit; however acetone with 2% water fitted the 
criterion well. Liquid paraffin was used as the dispersion media or external phase. Petroleum 
ether was used to clean the microparticles since it removesliquid paraffin without affecting the 
integrity of the microparticles. 
Results are shown in Table 2. The drug content was found to be very high in all the cases 
probably due to polymer loss by adherence to the container as a result of viscous nature of slurry. 
The incorporation efficiency was found to be good in all formulations. Highest incorporation 
efficiency 96.48 % was found in batch of MC6. Entrapment efficiency increase with increase in 
the polymer concentration from the results it can be inferred that there is a proper distribution of 
Albendazole in the microcapsules and the deviation is withinthe acceptable limits. 
The arithmetic mean particle size of the formulations was determined by the optical microscope 
fitted with an ocular micrometer and stage micrometer. In general mean particle size of the 
microcapsules significantly increases with increase in polymer concentration due to high 
viscosity of medium at a higher polymer concentration resulting in enhanced interfacial tension 
and diminished shearing efficiency.  
The angle of repose of microcapsule ranges from 18-22.5° (table 2). The values of angles of 
repose indicate excellent flow properties. 
In vitro release studies were carried out by employing USP XXIII rotating basket method. The 
release profile obtained for all the six formulations in 10 hrs. The release of drug from polymer 
matrix takes place after complete swelling of the polymer and as the amount of polymer in the 
formulation increases the time required to swell alsoincrease thereby decrease in the drug 
release. However, the release showed a biphasic release with an initial burst effect. Maximum 
drug release was shown by microcapsules formulation of batch MC6 (90.18 %) and minimum 
release is shown by formulation of batch MC3 (63.7%). 
CONCLUSION 
Different microcapsules formulations wereprepared by solvent evaporation method using 
different polymers like Eudragit RS-100, chitosan and HPMC. From the results it seems that 
 formulation MC6 was found to be satisfactory in terms of excellent micromeritic properties, 
yield of microcapsule, (97±0.46 %), incorporation efficiency (96.48±0.38%) and highest in vitro 
drug release of 90.18 %) % in a sustained manner with constant fashion over extended period of 
time for 10 hrs. Hence the prepared Albendazole microcapsules may prove to be potential 
candidate for safe and effective sustained drug delivery. 
Further in-vivo investigation is required to establishefficacy of these formulations.  
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